
Fact Sheet: 340B Drug Pricing Program

Background:

The 340B Drug Pricing Program is a federal program created in 1992 to help safety-net hospitals and clinics serve patients with limited financial resources. Under the program, eligible providers can purchase certain outpatient medicines at deeply discounted prices. These savings are intended to help providers expand care and improve access to treatment for vulnerable patients.

In short, 340B was designed to help safety-net providers reach more patients with limited resources.

The current 340B Drug Pricing Program can be harmful to patients.



People living with autoimmune and autoinflammatory arthritis often depend on specialty and biologic medicines to manage their disease, with treatments sometimes costing tens of thousands of dollars each year. When working as intended, the 340B Program can improve access to these medications, reduce financial strain, and support consistent treatment. However, there is limited transparency around how savings are used and whether patients directly benefit. Many patients do not see lower out-of-pocket costs or better access to medicines. In addition, the use of outside partners including contract pharmacies and inconsistent patient support can make it harder for savings to reach those who need them most.

What can be done?

Patients and caregivers can share their stories so policymakers understand how drug access and affordability impact real lives. Staying informed about programs like 340B helps people advocate for meaningful improvements that put patients first. Connecting with AiArthritis is another way to stay engaged, amplify patient voices, and help ensure people living with autoimmune disease are represented in healthcare policy discussions. Your insights can impact policy to better the patient experience. We don't represent the patient voice, we are the patient voice!

In conclusion

The 340B Drug Pricing Program was created to help patients access needed medications, support uninsured and underinsured individuals, expand services like specialty care and education, and stretch limited healthcare resources. While most stakeholders agree the program should work for patients, many people are not experiencing its intended benefits today. Limited transparency, inconsistent patient support, and the use of outside partners can make it harder to know whether savings are truly reaching patients through lower costs or better access to medicines. That is why it is so important for patients and caregivers to share their experiences and continue learning about 340B reform. Patients deserve a program that delivers the support and benefits it was designed to provide.

Hear from our patients!

Scan the QR code to hear patient stories and learn about our policy priorities in our Knowledge=Empowerment classroom

AiARTHRITIS
INTERNATIONAL FOUNDATION FOR AUTOIMMUNE & AUTOINFLAMMATORY ARTHRITIS